A phase 1 human immunodeficiency virus vaccine trial for cross-profiling the kinetics of serum and mucosal antibody responses to CN54gp140 modulated by two homologous prime-boost vaccine regimens (Frontiers in Immunology, 2017)

(untitled) - Kratochvil, S; McKay, P; Kopycinski, J; Bishop, C; Hayes, P; Muir, L; Pinder, C; Cizmeci, D; King, D; Aldon, Y; Wines, B; Hogarth, P; et al.